New Drug Approvals

Home » Posts tagged 'SETILEUTON'

Tag Archives: SETILEUTON

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Paypal donate

Blog Stats

  • 1,445,983 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,869 other followers

Follow New Drug Approvals on WordPress.com

Categories

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,869 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

Verified Services

View Full Profile →

Categories

Flag Counter

MK 0633, SETILEUTON


SETILEUTON.pngstr1

Figure

MK 0633, SETILEUTON

(-)-enantiomer

910656-27-8 CAS free form

MW 463.3817, C22 H17 F4 N3 O4  FREE FORM

Tosylate cas 1137737-87-1

2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-

4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one

Image result for Merck Frosst Canada Ltd.

WO2006099735A1

Inventors Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
WO 2006099735 A1Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce Mackay, Richard Friesen
Applicant Merck Frosst Canada Ltd.

Image result for Merck Frosst Canada Ltd.

MK-0633 had been in early clinical development for several indications, including the treatment of chronic obstructive pulmonary disease (COPD), asthma and atherosclerosis

Leukotriene metabolism plays a central role in inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and atherosclerosis. In particular, the activation of the enzyme 5-lipoxygenase (5-LO) and its associated protein, 5-LO activating protein (FLAP), initiates a cascade that transforms arachidonic acid into inflammatory leukotrienes

Inhibition of leukotriene biosynthesis has been an active area of pharmaceutical research for many years. The leukotrienes constitute a group of locally acting hormones, produced in living systems from arachidonic acid. Leukotrienes are potent contractile and inflammatory mediators deπved by enzymatic oxygenation of arachidonic acid by 5-hρoxygenase. One class of leukotriene biosynthesis inhibitors are those known to act through inhibition of 5 -lipoxygenase (5-LO).
The major leukotrienes are Leukotriene B4 (abbreviated as LTB4), LTC4, LTD4 and LTE4. The biosynthesis of these leukotrienes begins with the action of the enzyme 5-lipoxygenases on arachidonic acid to produce the epoxide known as Leukotriene A4 (LT A4), which is converted to the other leukotπenes by subsequent enzymatic steps. Further details of the biosynthesis as well as the metabolism of the leukotπenes are to be found in the book Leukotrienes and Lipoxygenases, ed. J. Rokach, Elsevier, Amsterdam (1989). The actions of the leukotπenes in living systems and their contπbution to various diseases states are also discussed in the book by Rokach.
In general, 5 -LO inhibitors have been sought for the treatment of allergic rhinitis, asthma and inflammatory conditions including arthπtis. One example of a 5-LO inhibitor is the marketed drug zileuton (ZYLOFT®) which is indicated for the treatment of asthma. More recently, it has been reported that 5-LO may be an important contributor to the atherogenic process; see Mehrabian, M. et al., Circulation Research, 2002 JuI 26, 91(2): 120-126.
Despite significant therapeutic advances in the treatment and prevention of conditions affected by 5-LO inhibition, further treatment options are needed. The instant invention addresses that need by providing novel 5-LO inhibitors which are useful for inhibiting leukotriene biosynthesis.

Image result for mk 0633

Synthesis of coumarin intermediate in MK-0633. Reagents and conditions: a) 2.7 M H2SO4 (1 mL/1 mmol), 1.1 equiv. NaNO2, –5 °C, 15 min, 1.5 equiv. KI (1 M H2SO4, 1 mL/0.5 mmol), 0–70 °C, 20 min; b) 1.5 equiv. CuCN, DMF, 110 °C, 24 h, 72 % (over two steps); c) 0.05 equiv. H2SO4, MeOH, 60 °C, 12 h, 81 %; d) 2.5 equiv. 2 M AlMe3, 1.5 equiv. NH(OMe)Me·HCl, THF, room temp., 24 h, 86 %; e) 4.0 equiv. C6H4FMgBr, THF, 0 °C to room temp., 3 h, 74 %; f) toluene, reflux, 24 h, 83 %.

Study of the Chemoselectivity of Grignard Reagent Addition to Substrates Containing Both Nitrile and Weinreb Amide Funct…

Article · Aug 2013 · European Journal of Organic Chemistry
Paper
Synthesis of 4-arylcoumarins via palladium-catalyzed arylation/cyclization of ortho-hydroxylcinnamates with diaryliodonium salts
Tetrahedron Letters (2015), 56, (24), 3809-3812

An efficient method for the palladium-catalyzed arylation/cyclization of ortho-hydroxylcinnamate ester derivatives with diaryliodonium salts is described. A range of 4-arylcoumarins are obtained in good to excellent yield. Furthermore, the route can be applied to the synthesis of versatile building block of 5-lipoxygenase inhibitor.

Image for unlabelled figure

PATENT

WO 2006099735

EXAMPLE 7
(+) and (-)-4-(4-Fluorophenyl)-7-[(|5-[l-hvdroxy-l-(tnfluoromethyl)propyn-K3,4-oxadiazol-2-vUammo)methyl1-2H-chromen-2-one
Step 1: Ethyl 2-hvdroxy-2-(trifluoromethyl)butanoate

To a -78 0C solution of ethyl tπfluoropyruvate (129 0 g 758 mmol) in ether was added dropwise withm 90 mm a solution of EtMgBr 3.0 M m ether (252 mL). The solution was brought over one Ih to ca. -10 0C and poured over 2L of saturated NH4Cl. The layers were separated and the aqueous phase extracted with ether (3 X 500 mL) The organic phases were combined, dried over MgSO4 and the solvent removed. Distillation at 50-65 0C (30 mm Hg) gave the title compound. 1H NMR (400 MHz, acetone- d6): δ 5.4 (s, IH), 4.35 (q, 2H), 2.07 (m, IH), 1.83 (m, IH), 1.3 (t, 3H) and 0.93 (t, 3H).
Step 2: 2-Hvdroxy-2-(tπfluoromethyl)butanohvdrazide

The ethyl ester of step 1 (50.04 g, 250 mmol) and hydrazine hydrate (25.03 g, 50 mmol) were heated at 80 0C for 18 h. The excess hydrazine was removed under vacuum and the crude product was filtered through a pad of silica gel with EtOAc-Hexane (ca. 3L) to furnish the title compound. 1H NMR (400 MHz, acetone-d6): δ 9.7 (s, IH), 6.10 (s, IH), 2.25 (m, IH), 1.85 (m, IH) and 0.95 t, (3H). Step 3: 2-(5-Ammo-l ,3,4-oxadiazol-2-yl)-l , 1 , l-tπfluorobutan-2-ol

To hydrazide (34.07 g, 183 mmol) of step 2 m 275 mL of water was added KHCO3 (18.33 g, 183 mmol) followed by BrCN (19.39 g, 183 mmol) portionwise. After 3h, the solid was filtered, washed with cold water and dπed to afford the title compound. Additional compound could be recovered from the aqueous phase by extraction (ether-hexane, 1:1). 1H NMR (400 MHz, acetone-d6): δ 6.54 (s, 2H), 6.01 (s, IH), 2.22 (m, IH), 2.08 (m, IH) and 0.99 (m, 3H).
Step 4: 4-(4-Fluorophenyl)-7-|Y { 5-[ 1 -hydroxy- 1 -(tnfluoromethyl)propyll -1,3,4- oxadiazol-2-yl}amino)methyl1-2H-chromen-2-one


A mixture of oxadiazole (14.41 g, 68.2 mmol) of step 3 and 4-(4-fluorophenyl)-2-oxo-2H-chromene-7-carbaldehyde (14.1 g, 52.5 mmol) in toluene (160 mL) with 10% of PPTS was brought to reflux and let go overnight. The system was equipped with a Dean-Stark trap to collect water. The solvent was removed and the crude oil (1H NMR (400 MHz, acetone-d6): δ 9.33 (IH, s, imme)) obtained was diluted in EtOH (ca. 75 mL) at 0 0C. To this solution was added NaBH4 (1.9 g) portionwise and the reaction was quenched with a solution OfNH4Cl after 45 mm. The mixture was saturated with NaCl and extracted with EtOAc (3 X 200 mL). The organic phases were combined and dried over MgSO4.
Purification over silica gel chromatography using toluene-EtOAc (55.45) gave the title compound . 1H NMR (400 MHz, acetone-d6): δ 7.65 (m, 2H), 7.50 (m, 3H), 7.38 (m, 3H), 6.35 (s, IH), 6.06 (s, IH), 4.70 (m, 2H), 2.21 (m, IH), 2.11 (m, IH) and 0.98 (t, 3H).
Step 5: Separation on chiral HPLC column of (+) and (-) enantiomers of 4-(4-fluorophenyl)-7- [((5-ri-hvdroxy-l-(trifluoromethyl)propyl1-l,3,4-oxadiazol-2-yl}amino)methvn-2H- chromen-2-one

A solution of (±)-4-(4-fluorophenyl)-7-[({5-[l-hydroxy-l-(trifluoromethyl)propyl]-l,3,4-oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one (0.5-0.6 g) in EtOΗ-Ηexane (30:70, ca. 40 mL) was injected onto a CΗIRALPAK AD® preparative (5cm x 50cm) ΗPLC column (eluting with
EtOΗ/Ηexane, 30/70 with UV detection at 280 nm). The enantiomers were separated with the faster eluting enantiomer having a retention time of – 34 mm for the (-)-enantiomer and the slower eluting enantiomer having a retention time of ~ 49 mm for the (+)-enantiomer.

PAPER

The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor

Merck Frosst Centre for Therapeutic Research, 16711 Trans Canada Highway, Kirkland, Quebec, Canada H9H 3L1
ACS Med. Chem. Lett., 2010, 1 (4), pp 170–174
DOI: 10.1021/ml100029k
Publication Date (Web): April 13, 2010
Copyright © 2010 American Chemical Society
*To whom correspondence should be addressed. E-mail: yves_ducharme@merck.com.
Abstract Image
The discovery of novel and selective inhibitors of human 5-lipoxygenase (5-LO) is described. These compounds are potent, orally bioavailable, and active at inhibiting leukotriene biosynthesis in vivo in a dog PK/PD model. A major focus of the optimization process was to reduce affinity for the human ether-a-go-go gene potassium channel while preserving inhibitory potency on 5-LO. These efforts led to the identification of inhibitor (S)-16 (MK-0633, setileuton), a compound selected for clinical development for the treatment of respiratory diseases.
4-(4-fluorophenyl)-7-[({5-[(2R)-1,1,1-trifluoro-2-hydroxybutan-2-yl]- 1,3,4-oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one ((R)-16) and 4-(4- fluorophenyl)-7-[({5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2- yl}amino)methyl]-2H-chromen-2-one ((S)-16)
str1
A solution of (±)-4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4- oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one (16) (0.5-0.6 g) in EtOH-Hexane (30:70, ca. 40 mL) was injected on a CHIRALPAK AD preparative (5 cm x 50 cm) HPLC column (eluting with EtOH/Hexane, 30/70 with UV detection at 280 nm). The enantiomers were separated with the fast-eluting enantiomer having a retention time of ~ 34 min for the (-) and the slow-eluting enantiomer having a retention time of ~ 49 min for the (+)-enantiomer.
4-(4-fluorophenyl)-7-[({5-[(2S)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol- 2-yl}amino)methyl]-2H-chromen-2-one ((S)-16, MK-0633, setileuton):
str1
A mixture of oxadiazole (S)-35 (41.9 g, 156 mmol) and aldehyde 25 (39.2 g, 186 mmol) in toluene (2 L) with 10% of pyridinium p-toluenesulfonate was refluxed overnight. The system was equipped with a Dean-Stark apparatus to collect water. The solvent was removed and the crude oil [1 H NMR (400 MHz, acetone-d6): δ 9.33 (s, 1H, imine)] obtained was diluted in THF (600 mL) and EtOH (100 mL). To this solution was added at 0 o C NaBH4 (7.2 g) portionwise. After 1 h of stirring, aqueous ammonium acetate was added. The mixture was extracted with ethyl acetate. The combined organic fractions were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified on silica gel (toluene/EtOAc; 1:1) to give the title compound (39.4 g, 54%).
FREE FORM
1 H NMR (400 MHz, acetone-d6): δ 7.65 (m, 2H), 7.50 (m, 3H), 7.38 (m, 3H), 6.35 (s, 1H), 6.06 (s, 1H), 4.70 (m, 2H), 2.21 (m, 1H), 2.11 (m, 1H), 0.98 (t, 3H);
HRMS calcd for C22H17F4N3O4 [MH+]: 464.1233; found: 464.1228.
PATENT
Image result for mk 0633

CLIP

J. Org. Chem. 2010, 75, 4154−4160

Synthesis of a 5-Lipoxygenase Inhibitor

 Abstract Image

Practical, chromatography-free syntheses of 5-lipoxygenase inhibitor MK-0633 p-toluenesulfonate (1) are described. The first route used an asymmetric zincate addition to ethyl 2,2,2-trifluoropyruvate followed by 1,3,4-oxadiazole formation and reductive amination as key steps. An improved second route features an inexpensive diastereomeric salt resolution of vinyl hydroxy-acid 22 followed by a robust end-game featuring a through-process hydrazide acylation/1,3,4-oxadiazole ring closure/salt formation sequence to afford MK-0633 p-toluenesulfonate (1).


Leukotriene metabolism plays a central role in inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and atherosclerosis. In particular, the activation of the enzyme 5-lipoxygenase (5-LO) and its associated protein, 5-LO activating protein (FLAP), initiates a cascade that transforms arachidonic acid into inflammatory leukotrienes. Consequently, compounds that can inhibit 5-LO have potential as new treatments for the conditions listed above. Gosselin and co-workers at Merck describe two routes towards one such compound (MK-0633) brought forward as a development candidate at Merck ( J. Org. Chem. 2010, 75, 4154−4160). The first route used an asymmetric zincate addition to ethyl 2,2,2-trifluoropyruvate followed by 1,3,4-oxadiazole formation and reductive amination as key steps. An improved second route (shown here) featured an inexpensive diastereomeric salt resolution of a vinyl hydroxy-acid followed by a through-process hydrazide acylation/1,3,4-oxadiazole ring-closure/salt-formation sequence to afford MK-0633 as the p-toluenesulfonate salt.

A Practical Synthesis of 5-Lipoxygenase Inhibitor MK-0633

Department of Process Research, Merck Frosst Centre for Therapeutic Research, 16711 Route Transcanadienne, Kirkland, Québec, Canada H9H 3L1
Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065
J. Org. Chem., 2010, 75 (12), pp 4154–4160
DOI: 10.1021/jo100561u
MK-0633 tosylate salt (1) was obtained as a white solid (6.64 kg, 91.4% yield): mp 164−165 °C;
[α]20D − 0.86 (c 10.0, EtOH);
1H NMR (500 MHz, DMSO-d6) δ 8.58 (1 H, t, J = 6.2 Hz), 7.62 (2 H, dd, J = 8.3, 5.4 Hz), 7.49 (2 H, d, J = 7.8 Hz), 7.47−7.38 (4 H, m), 7.33 (1 H, d, J = 8.3 Hz), 7.13 (2 H, d, J = 7.7 Hz), 6.44 (1 H, s), 4.53 (2 H, d, J = 5.6 Hz), 2.30 (3 H, s), 2.17−2.05 (1 H, m), 2.03−1.93 (1 H, m), 0.90 (3 H, t, J = 7.37 Hz);
13C NMR (125 MHz, DMSO-d6) δ 164.1, 162.9 (d, J = 246.8 Hz), 159.6, 156.1, 153.7, 153.6, 145.5, 143.7, 137.7, 131.1 (d, J = 3.5 Hz), 130.9 (d, J = 8.7 Hz), 128.1, 126.8, 125.4, 124.5 (q, J = 286.6 Hz), 123.5, 117.4, 115.9 (d, J = 22.0 Hz), 115.4, 114.7, 73.7 (q, J = 28.6 Hz), 45.4, 26.1, 20.8, 7.0;
19F NMR (375 MHz, DMSO-d6) δ −79.7, −113.1;
HRMS calcd for C22H18F4N3O4 [M + H] 464.1228, found 464.1246.
IR (cm−1, NaCl thin film) 3324, 3010, 2977, 1735, 1716, 1618, 1510, 1428, 1215, 1178.
HPLC analysis: eclipse XDB-phenyl column 4.6 mm × 15 cm (0.1% aq H3PO4/CH3CN 65:35 to 10:90 over 50 min, 1.0 mL/min, 210 nm, 25 °C); MK-0633 (1) tR = 16.86 min. Chiral HPLC analysis: Chiralpak AD-H column 4.6 mm × 25 cm (EtOH/hexane 60:40, hold 15 min, 0.5 mL/min, 300 nm, 30 °C); (S)-enantiomer tR = 9.5 min; (R)-enantiomer tR = 11.5 min.
1 to 6 of 6
Patent ID Patent Title Submitted Date Granted Date
US2016193168 Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors 2015-11-30 2016-07-07
US2013251787 Treatment of Pulmonary Hypertension with Leukotriene Inhibitors 2013-03-15 2013-09-26
US7915298 Compounds and methods for leukotriene biosynthesis inhibition 2009-04-02 2011-03-29
US2009227638 Novel Pharmaceutical Compounds 2009-09-10
US7553973 Pharmaceutical compounds 2007-06-28 2009-06-30
US2009030048 Novel pharmaceutical compounds 2009-01-29
/////////////MK 0633, PHASE 2
CCC(C1=NN=C(O1)NCC2=CC3=C(C=C2)C(=CC(=O)O3)C4=CC=C(C=C4)F)(C(F)(F)F)O
Advertisements
%d bloggers like this: